Who is sponsoring NCT01805076?

NCT01805076 is sponsored by Alliance for Clinical Trials in Oncology.

What drugs are being tested in NCT01805076?

Interventions in NCT01805076: Breast surgery, Magnetic resonance imaging, Mammography.

What condition does NCT01805076 study?

NCT01805076 studies Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Triple-negative Breast Cancer.

Is NCT01805076 still recruiting?

NCT01805076 is currently completed. Last updated 5 September 2025.

Last reviewed 2025-09-05 · How we verify

NCT01805076

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MRI and Mammography Before Surgery in Patients With Stage I-II Breast Cancer

Completed Phase 3 Last updated 5 September 2025

What this trial tests

Phase 3 trial testing Breast surgery in Estrogen Receptor-negative Breast Cancer in 317 participants. Completed in 27 May 2025.

Timeline

21 May 2014

Primary endpoint
27 May 2025

27 May 2025

Quick facts

Lead sponsor	Alliance for Clinical Trials in Oncology
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	317
Start date	21 May 2014
Primary completion	27 May 2025
Estimated completion	27 May 2025
Sites	179 locations across United States

Drugs / interventions tested

Breast surgery
Magnetic resonance imaging
Mammography

Conditions studied

Estrogen Receptor-negative Breast Cancer — all drugs for Estrogen Receptor-negative Breast Cancer →
Progesterone Receptor-negative Breast Cancer — all drugs for Progesterone Receptor-negative Breast Cancer →
Stage IA Breast Cancer — all drugs for Stage IA Breast Cancer →
Stage IB Breast Cancer — all drugs for Stage IB Breast Cancer →

Sponsor

Alliance for Clinical Trials in Oncology

Who can join

18 and older, female only, with Estrogen Receptor-negative Breast Cancer or Progesterone Receptor-negative Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test whether patients undergoing a breast MRI (magnetic resonance imaging) before breast surgery will have better results after the surgery. Breast tumors are routinely evaluated using mammograms and ultrasound before surgery. This study would like to find out if using MRI in addition to mammography before surgery improves our ability to evaluate tumors and decide what kind of surgery is best for the patient.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Imaging in Locoregional Management of Breast Cancer.
Kuhl CK, Lehman C, Bedrosian I. · · 2020 · cited 16× · PMID 32442068 · DOI 10.1200/jco.19.03257
Preoperative magnetic resonance imaging use and oncologic outcomes in premenopausal breast cancer patients.
Zeng Z, Amin A, Roy A, Pulliam NE, et al · · 2020 · cited 12× · PMID 33083528 · DOI 10.1038/s41523-020-00192-7
Breast Magnetic Resonance Imaging for Patients With Newly Diagnosed Breast Cancer: A Review.
Kim SY, Cho N. · · 2022 · cited 7× · PMID 36031752 · DOI 10.4048/jbc.2022.25.e35
Trends in use of magnetic resonance imaging and partial breast irradiation between 2011-2022 in the Netherlands: A population-based study.
Civil YA, Eijkelboom AH, Veldink AE, van Maaren MC, et al · · 2025 · PMID 40979174 · DOI 10.1016/j.ctro.2025.101039

Verify or expand the search:

Other trials of Breast surgery

Trials testing the same drug.

NCT05876390 — Impact of Regional Anesthesia on Chronic Post-operative Pain · enrolling by invitation
NCT04866147 — Prediction of Chronic Postsurgical Pain in Adults · completed
NCT02907918 — Neoadjuvant Study of Palbociclib in Combination With Letrozole and Trastuzumab in Stage II-III ER+ HER2+ Breast Cancer · Phase 2 · terminated
NCT02789657 — Neoadjuvant Therapy in Clinical Stage I-III HER2-positive Breast Cancer. · Phase 2 · completed

Other Alliance for Clinical Trials in Oncology trials

Trials by the same sponsor.

NCT07293247 — A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After · Phase 2 · not yet recruiting
NCT07283939 — Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays · NA · recruiting
NCT07059884 — Distance-Based Exercise to Preserve Function and Prevent Disability · NA · recruiting
NCT07321652 — Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C · Phase 3 · not yet recruiting
NCT07091617 — Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01805076 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology
Last refreshed: 5 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01805076.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing